Common drug tested for mysterious skin disease linked to parasite outbreaks
NCT ID NCT06251739
Summary
This early study tested whether oral ivermectin could safely treat PKDL, a skin disease that appears after recovery from kala-azar (visceral leishmaniasis). Researchers compared ivermectin taken for three months against the standard 12-week miltefosine treatment in 30 patients in Bangladesh. The goal was to find a shorter, safer treatment option since current therapies are lengthy and can cause side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST KALA-AZAR DERMAL LEISHMANIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
International Centre for Diarrhoeal Disease Research, Bangladesh
Dhaka, Dhaka Division, 1212, Bangladesh
Conditions
Explore the condition pages connected to this study.